Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008

Novartis

Status and phase: Completed; Phase 3

Conditions: Seasonal Influenza; Vaccine

Treatments: Biological: trivalent split influenza vaccine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00498303

2007-001403-38

V44P11S

Details and patient eligibility

About

Annual trial for registration of trivalent split influenza vaccine with the strain composition of the season 2007/2008 in healthy adult and elderly subjects

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• ≥ 18 years of age, mentally competent, willing and able to give informed consent prior to study entry
• available for all the visits scheduled in the study and able to comply with all study requirements
• in good health as determined by: medical history, physical examination, clinical judgment of the investigator

Exclusion criteria

• n/a

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)